Nektar Therapeutics | NKTR - 股票



金融业
股票价格
USD
资产
USD 280.41M
现金及等价物
USD 15.12M
销售成本
USD 4.44M
流动资产
USD 266.27M
流动负债
USD 53.54M
债务
USD 0
股息收益率
0
EBIT
USD -19.09M
EBITDA
USD -31.81M
员工
137
EPS每股收益
USD -1.35
股本和储备
USD 89.83M
销售毛利
USD 21.81M
债务利息支出
USD 9.77M
利息收入
USD -0.18
贷款资金
USD 63.16M
市值
USD 12.53B
净收入
USD -36.08M
营业费用
USD 40.9M
营业利润
USD -19.09M
普通股股本
USD 20.38M
税前利润
USD -34.7M
销售收入
USD 21.81M
销售和管理费用
USD 10.17M
股票
USD 14.46M
贸易债权人
USD 10.77M
应收帐款人
USD 1.78M


股票 更改 日
Agios Pharmaceuticals USD 35.09M 2.17M 2026-03
ALKERMES USD 336.7M 140.08M 2026-03
Amgen USD 6.19B 39M 2026-03
Baxter International USD 2.32B 84M 2026-03
BioCryst Pharmaceuticals USD 5.98M 587K 2026-03
Biogen USD 1.95B 219.1M 2026-03
Bristol-Myers Squibb USD 2.76B 66M 2026-03
Cara Therapeutics USD 900K 0 2025-03
Cipla INR 61.6B 5.18B 2025-09
Dr.Reddys Laboratories INR 79.01B 3.19B 2025-12
Eisai JPY 236.46B 9.14B 2025-09
Eli Lilly USD 14.53B 785M 2026-03
Exelixis USD 26.6M 4.92M 2026-03
Gilead Sciences USD 1.91B 140M 2026-03
GlaxoSmithKline GBP 6.16B 233M 2026-03
Grifols EUR 3.56B 63.19M 2024-12
Halozyme Therapeutics USD 155.47M 21.01M 2026-03
Incyte USD 115.62M 14.56M 2026-03
Ionis Pharmaceuticals USD 5.56M 4.49M 2026-03
Karyopharm Therapeutics USD 4.04M 72K 2025-12
MacroGenics USD 9.5M 1.59M 2026-03
Merck USD 6.48B 179M 2026-03
Nektar Therapeutics USD 14.46M 1.78M 2024-06
Neurocrine Biosciences USD 64.5M 4.5M 2026-03
Novartis USD 6.29B 17M 2026-03
Pfizer USD 10.67B 13M 2026-03
Roche Holding CHF 7.6B 9M 2025-06
Sarepta Therapeutics USD 1B 86.37M 2026-03
Takeda JPY 1.41T 107.71B 2025-12
Teva Pharmaceutical Industries USD 3.18B 144M 2025-12